Ardelyx, Inc. (ARDX): Depreciation & Amortization

Annual figures by period end, from SEC filings.

$3.06M
Year ended 2025-12-31
$3.35M
Trailing 12 months to 2026-06-30
+38.8%
3-year compound annual growth
+3.8%
5-year compound annual growth
2020-12-31: $2.54M2021-12-31: $2.81M2022-12-31: $1.14M2023-12-31: $1.29M2024-12-31: $2.06M2025-12-31: $3.06M$3.06M
2020-12-31 Depreciation & Amortization (USD) 2025-12-31
Period endedDepreciation & AmortizationChange YoYSource filing
2025-12-31$3.06M+48.3%2026-02-19, From 2025-01-01
2024-12-31$2.06M+59.7%2026-02-19, From 2024-01-01
2023-12-31$1.29M+12.9%2026-02-19, From 2023-01-01
2022-12-31$1.14M-59.2%2025-02-20, From 2022-01-01
2021-12-31$2.81M+10.5%2024-02-22, From 2021-01-01
2020-12-31$2.54Mn/a2023-03-02, From 2020-01-01

Depreciation & Amortization at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedDepreciation & AmortizationChange YoY
Ardelyx, Inc. (ARDX)2025-12-31$3.06M+48.3%
Zai Lab Ltd (ZLAB)2025-12-31$15.01M+26.6%
MannKind Corp (MNKD)2025-12-31$12.28M+66.7%
Nature's Sunshine Products Inc (NATR)2025-12-31$13.84M-2.6%
Travere Therapeutics, Inc. (TVTX)2025-12-31$60.74M+39.5%
BridgeBio Pharma, Inc. (BBIO)2025-12-31$5.43M-10.6%
Mirum Pharmaceuticals, Inc. (MIRM)2025-12-31$24.24M+2.6%
HUTCHMED (China) Ltd (HCM)2025-12-31$13.31M+7.8%
Evolus, Inc. (EOLS)2025-12-31$7.51M+41.7%

Compare ARDX, ZLAB, MNKD, NATR side by side · Screen every company in Pharmaceutical Preparations ↗